Back to News
Market Impact: 0.25
ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & Outlook
ProKidney said it remains on track to report top-line interim analysis results from its Phase III PROACT 1 study in Q2 2027. Patient recruitment for its investigational autologous cell therapy, rilparencel, was stronger than expected; no trial results or other financial figures were reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PROK0.45
More News
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- SK Hynix says the memory-chip shortage will last until 2030—and more than half its production is booked for the next two years
- GE Vernova shares slip despite a beat-and-raise. What the sellers are getting wrong
- Microsoft’s strong quarter backs up its stock rebound. Here's our new price target
- Google struggling to make AI Mode searches pay
- As Waymo expands overseas, it remains a niche cash-burning business